LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DNA-Based Tests Developed for Rare Blood Group

By LabMedica International staff writers
Posted on 08 Apr 2013
The genetic underpinnings of most blood group antigens have been identified, a few have stubbornly eluded discovery in spite of intense efforts motivated by their clinical significance.

Identification of genetic polymorphisms has allowed important improvements in transfusion safety and obstetrics, especially with the recent development of high-throughput platforms for blood group genotyping.

Scientists at the University of Vermont (Burlington VT, USA) working with French colleagues, have discovered the biochemical and genetic basis of the Vel blood group antigen, which has been a worrisome mystery for decades, especially as anti-Vel regularly causes severe hemolytic transfusion reactions. Vel negative (Vel−) blood is one of the most difficult blood types to supply in many countries. This is partly due to the rarity of the Vel− blood type, but also to the lack of systematic screening for the Vel− blood type in blood donors.

The Vel carrier protein was identified by mass spectrometry-based sequencing. Mass spectrometry-based de novo peptide sequencing identified this protein to be a small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. A cohort of 70 Vel− individuals was found to be uniformly homozygous for a 17-nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel− blood type facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms and can be completed in a few hours or less.

Bryan Ballif, PhD, the lead author of the study said, "Our findings promise to provide immediate assistance to healthcare professionals should they encounter this rare but vexing blood type. Identifying and making available rare blood types such as Vel-negative blood brings us closer to a goal of personalized medicine. Even if you are that rare one person out of 2,500 that is Vel-negative, we now know how to rapidly type your blood and find blood for you, should you need a transfusion." The study was published on March 23, 2013, in the journal EMBO Molecular Medicine.

Related Links:
University of Vermont

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Sample Transportation System
Tempus1800 Necto

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more